AbbVie Forecast, price target & analysts
AbbVie Target price 2025 - Analyst rating & recommendation
AbbVie Classifications & Recommendation:
AbbVie Price Target
| Target Price | $222.87 |
| Price | $222.47 |
| Potential |
0.18%
register free of charge
|
| Number of Estimates | 31 |
|
31 Analysts have issued a price target AbbVie 2026 .
The average AbbVie target price is $222.87.
This is
0.18%
register free of charge
$273.00
22.71%
register free of charge
$171.70
22.82%
register free of charge
|
|
| A rating was issued by 37 analysts: 26 Analysts recommend AbbVie to buy, 11 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the AbbVie stock has an average upside potential 2026 of
0.18%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 56.33 | 61.89 |
| 3.71% | 9.86% | |
| EBITDA Margin | 44.17% | 46.48% |
| 4.98% | 5.23% | |
| Net Margin | 7.52% | 35.03% |
| 15.22% | 365.64% |
31 Analysts have issued a sales forecast AbbVie 2025 . The average AbbVie sales estimate is
This results in the following potential growth metrics:
20 Analysts have issued an AbbVie EBITDA forecast 2025. The average AbbVie EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
33 AbbVie Analysts have issued a net profit forecast 2025. The average AbbVie net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.39 | 12.27 |
| 12.13% | 413.39% | |
| P/E | 18.09 | |
| EV/Sales | 7.37 |
33 Analysts have issued a AbbVie forecast for earnings per share. The average AbbVie EPS is
This results in the following potential growth metrics and future valuations:
Current AbbVie Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Berenberg |
Locked
➜
Locked
|
Locked | Sep 17 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Sep 16 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Sep 15 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Sep 12 2025 |
| BMO Capital |
Locked
➜
Locked
|
Locked | Sep 12 2025 |
| Raymond James |
Locked
➜
Locked
|
Locked | Aug 01 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 01 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Berenberg:
Locked
➜
Locked
|
Sep 17 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Sep 16 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Sep 15 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Sep 12 2025 |
|
Locked
BMO Capital:
Locked
➜
Locked
|
Sep 12 2025 |
|
Locked
Raymond James:
Locked
➜
Locked
|
Aug 01 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 01 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
